FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Full approval will depend on verification of clinical benefit in a confirmatory trial
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Subscribe To Our Newsletter & Stay Updated